drugset / Trial / NCT05004805
COVID-19 Methylene Blue Antiviral Treatment
Phase 2
Completed
24 enrolled
Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences
Irkutsk State Medical University · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a pilot study of a single-center, blind, randomized, placebo-controlled, parallel-group study testing for the efficacy and safety of Methylene blue when administered topically as a 0.02% solution for nasopharyngeal and oropharyngeal irrigation in COVID-19 patients requiring hospitalization.
Timeline
- Start
- 2021-08-06
- Primary completion
- 2021-12-12
- Completion
- 2021-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylene Blue | Diagnostic / imaging agent | 0.02 % | Topical |